1. Aisen P, Leibman A, Zweier J. 1978. Stoichiometric and site characteristics of the binding of iron to human transferrin. J Biol Chem. 253(6): 1930-1937.
2. Andes D, Craig AW. 1998. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother. 42(9): 2375-2379.
3. Beacham RI. 1979. Periplasmic enzymes in gram-negative bacteria. Int J Biochem. 10(11): 877-883.
4. Berry V, Hoover J, Singley C, Woodnutt G. 2005. Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae. Antimicrob Agents Chemother. 49(3): 908-915.
5. Brink JA. 2019. Epidemiology of carbapenem-resistant gram-negative infections globally. Curr Opin Infect Dis. 32(6): 609-616. 66
6. Bulitta BJ, Hope WW, Eakin EA, Guina T, Tam HV, Louie A, Drusano LG, Hoover LJ. 2019. Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans. Antimicrob Agents Chemother. 63(5): e02307-02318.
7. Bogaerts P, Cuzon G, Naas T, Bauraing C, Deplano A, Lissoir B, Nordmann P, Glupczynski Y. 2008. Carbapenem-resistant Acinetobacter baumannii isolates expressing the blaoxa-23 gene associated with ISAba4 in Belgium. Antimicrob Agents Chemother. 52(11): 4205-4206.
8. Boucher H, Talbot G, Bradley J, Edwards J, Gilbert D, Rice L, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 48(1):1-12.
9. Braun V. 2001. Iron uptake mechanisms and their regulation in pathogenic bacteria. Int J Med Microbiol. 291(2): 67-79.
10. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA: https://www.cdc.gov/drugresistance/threat-report-2013/.
11. Centers for Disease Control and Prevention (CDC). 2019. CDC’s Antibiotic resistance threats in the United States, 2019. Centers for Disease Control and Prevention, Atlanta, 67 GA: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report508.pdf.
12. Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th edition. Document M7-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Clinical and Laboratory Standards Institute. 2020. Performance standards for antimicrobial susceptibility testing; 30th edition. Document M100. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Craig AW, Ebert CS. 1990. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl. 74:63-70.
15. Craig AW. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 26(1): 1-10.
16. Craig AW. 2002. The role of pharmacodynamics in effective treatment of communityacquired pathogens. Advanced Studies in Medicine. 2: 126-133.
17. Doi Y. 2019. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis. 69(Suppl. 7): S565-S575.
18. Faraldo-Gómez JD, Sansom MS. 2003. Acquisition of siderophores in gram-negative bacteria. Nat Rev Mol Cell Biol. 4(2):105-116.
19. Garcic A. 1979. A highly sensitive, simple determination of serum iron using chromazurol B. Clin Chim Acta. 94(2):115-119.
20. Grenier B, Autret E, Marchand S, Thompson R. 1987. Kinetic parameters of amikacin in cystic fibrosis children. Infection. 15(4): 295-299.
21. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. 2017. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study). Antimicrob Agents Chemother. 61(9): e00093-17.
22. Honeybourne D, Baldwin RD. 1992. The site concentrations of antimicrobial agents in the lung. J Antimicrob Chemother. 30(3): 249-60.
23. Hatano K, Wakai Y, Watanabe Y, Mine Y. 1994. Simulation of human plasma levels of β-lactams in mice by multiple dosing and the relationship between the therapeutic efficacy and pharmacodynamic parameters. Chemotherapy. 40(1):1-7.
24. Holloway BW. 1955. Genetic recombination in Pseudomonas aeruginosa. J Gen Microbiol. 13:572-581.
25. Holloway BW. 1975. Genetic organization of Pseudomonas. In: Clarke HP and Richmond HM. Genetics and biochemistry of Pseudomonas. John Wiley & Sons Ltd.. 133161.
26. Hoover JL, Lewandowski TF, Mininger CL, Singley CM, Sucoloski S, Rittenhouse S. 2017. A robust pneumonia model in immunocompetent rodents to evaluate antibacterial efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii. J Vis Exp. 2(119): 55068.
27. Isler B, Doi Y, Bonomo AR, Paterson LD. 2018. New treatment options against carbapenem-resistant Acinetobacter baumannii Infections. Antimicrob Agents Chemother. 63(1): e01110-18.
28. Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting gram-negative bacteria. J Antimicrob Chemother. 71(3): 670-677.
29. Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, Kohira N, Miyagawa S, Ishibashi N, Matsumoto S, Nakamura R, Tsuji M, Yamano Y. 2017. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria. Antimicrob Agents Chemother. 62(1): e01454-17.
30. Ito-Horiyama T, Ishii Y, Ito A, Sato T, Nakamura R, Fukuhara N, Tsuji M, Yamano Y, Yamaguchi K, Tateda K. 2016. Stability of novel siderophore cephalosporin S649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother. 60(7): 4384-4386.
31. Kallen A, Hidron A, Patel J, Srinivasan A. 2010. Multidrug resistance among gramnegative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect Control Hosp Epidemiol. 31(5):528-531.
32. Katsube T, Echols R, Wajima T. 2019. Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin. Clin Infect Dis. 69(Suppl. 7): S552S558.
33. Khan UA, Maryam L, Zarrilli R. 2017. Structure, genetics and worldwide spread of New Delhi metallo-β-lactamase (NDM): a threat to public health. BMC Microbiol. 17: 101.
34. Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, Rittenhouse S, Tsuji M, Yamano Y. 2015. In vitro antimicrobial activity of a siderophore cephalosporin, S649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother. 60(2): 729-734.
35. Köhler T, Michea-Hamzehpour M, Epp SF, Pechere JC. 1999. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother. 43(2):424-427.
36. Kretchmar SA, Reyes ZE & Raymond KN. 1988. The spectroelectrochemical determination of the reduction potential of diferric serum transferrin. Biochim Biophys Acta. 956(1): 85-94.
37. Kuroda N, Munekage T, Yamano Y. 2005. Bactericidal activity of doripenem using in vitro pharmacodynamic models. Jpn J Chemother. 53(Suppl. 1): 80-91.
38. Leemans E, Fisher JF, Mobashery S. 2014. The β-lactam antibiotics: their future in the face of resistance. In: Marinelli F and Genilloud O. Antimicrobials. new and old molecules in the Fight against multi-resistant Bacteria. Springer Switzerland AG. 59-84.
39. Lenhard RJ, Bulman PZ. 2019. Inoculum effect of β-lactam antibiotics. J Antimicrob Chemother. 74(10): 2825-2843.
40. Li J, Rayner RC, Nation LR, Owen JR, Spelman D, Tan EK, Liolios L. 2006. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 50(9): 2946-2950.
41. MacVane HS, Crandon LJ, Nichols WW, Nicolau PD. 2014. Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-β- lactamase-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother. 58(11): 7007-7009.
42. Matsui M, Suzuki S, Yamane K, Suzuki M, Konda T, Arakawa Y, Shibayama K. 2014. Distribution of carbapenem resistance determinants among epidemic and non-epidemic types of Acinetobacter species in Japan. J Med Microbiol. 63(Pt. 6): 870-877.
43. Matsuhashi M, Wachi M, Ishino F. 1990. Machinery for cell growth and division: penicillin-binding proteins and other proteins. Res Microbiol. 141(1): 89-103.
44. Miethke M, Marahiel MA. 2007. Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev. 71(3):413-451.
45. Mizuyachi K, Hara K, Wakamatsu A, Nohda S, Hirama T. 2011. Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects. Curr Med Res Opin. 27(12): 2261-2270.
46. Morill JH, Pogue MJ, Kaye SK, LaPlante LK. 2015. Treatment options for carbapenem-resistant Enterobacteriaceae infections. Open Forum Infect Dis. 2(2): ofv050.
47. Muller C, Hofer B, Desarbre E, Page MGP. 2010. Enhanced activity of the siderophore monosulfactam BAL30072 (BAL) against Acinetobacter in iron-limited conditions. abstr F1-2133. 50th Intersci Conf Antimicrob Agents Chemother, Washington, DC.
48. Nakamura R, Ito-Horiyama T, Takemura M, Toba S, Matsumoto S, Ikehara T, Tsuji M, Sato T, Yamano Y. 2019. In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models. Antimicrob Agents Chemother. 63(9): e02031-18.
49. Nakashima M, Uematsu T, Kanamaru M, Ueno K. 1992. Clinical phase 1 study of meropenem. Chemotherapy. 40(Suppl. 1): 258-275.
50. Neilands JB. 1981. Iron absorption and transport in microorganisms. Annu Rev Nutr. 1: 27-46.
51. Okumura K, Tsuji H, Takeda K, Fukuda I, Nagaki T, Takano M, Higo K, Kinami J. 1983. Absorption, distribution, metabolism and excretion of ceftazidime in mice, rats and rabbits. Chemotherapy. 31(Suppl. 3): 188-198.
52. Raymond NK, Dertz AE, Kim SS. 2003. Enterobactin: An archetype for microbial iron transport. Proc Natl Acad Sci. 100(7): 3584-3588.
53. Saisho Y, Katsube T, White S, Fukase H, Shimada J. 2018. Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for gram-negative bacteria, in healthy subjects. Antimicrob Agents Chemother. 62(3): e02163-17.
54. Sato T, Yamawaki K. 2019. Cefiderocol: Discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis. 69(Suppl. 7): S538-S543.
55. Singley C, Page R, Hoover J, Elefante P, DeMarsh P. 2011. Efficacy of a LeuRS inhibitor GSK2251052 against Enterobacteriaceae isolates using a computer-controlled infusion system to recreate human PK profiles in rats. poster 1508. 21st Eur Cong Clin Microbiol Infect Dis, Milan.
56. Singley C, Page R, Hoover J, Elefante P, DeMarsh P. 2011. Efficacy of a LeuRS inhibitor GSK2251052 against Pseudomonas aeruginosa using a computer-controlled infusion system to recreate human exposure profiles in rats. poster F2-1866. 51st Intersci Conf Antimicrob Agents Chemother, Chicago.
57. Smith G. 1991. A simple non-surgical method of intrabronchial instillation for the establishment of respiratory infections in the rat. Lab Anim. 25(1): 46-49.
58. Spratt BG. 1975. Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12. Proc Natl Acad Sci. 72(8): 2999-3003.
59. Sumita Y, Nouda H, Tada E, Kohzuki T, Kato M, Okuda T, Fukasawa M. 1992. Pharmacokinetics of meropenem, a new carbapenem antibiotic, parenterally administrated to laboratory animals. Chemotherapy. 40(Suppl. 1): 123-131.
60. Suzuki H, Nishimura Y, Hirota Y. On the process of cellular division in Escherichia coli: a series of mutants of E. coli altered in the penicillin-binding proteins. Proc Natl Acad Sci. 75(2): 664-668.
61. Tamaki S, Nakajima S, Matsuhashi M. 1977. Thermosensitive mutation in Escherichia coli simultaneously causing defects in penicillin-binding protein-1Bs and in enzyme activity for peptidoglycan synthesis in vitro. Proc Natl Acad Sci. 74(12): 5472-5476.
62. Tamura T, Ikedo M. 2011. Problems with the quality of minimum inhibitory concentration (MIC) measurement. Jpn J Chemother. 59(5): 460-468.
63. Tatsumi T, Fliss H. 1994. Hypochlorous acid mobilizes intracellular zinc in isolated rat heart myocyte. J Mol Cell Cardiol. 26(4): 471-479.
64. Tessier RP, Nicolau PD. 2013. Tigecycline displays in v ...